Prof. Slavin and HepC Therapeutics are researching new viral-based treatments for COVID-19
Prof. Slavin is now serving as the medical director of HepC Therapeutics, Budapest, Hungary in partnership with ProBioGen, Berlin, Germany is now involved in clinical application of another poultry virus for treatment of COVID-19. This new virus, an attenuated infectious bursal disease virus (IBDV) for post-exposure treatment of patients infected with SARS-CoV-2 can be applied orally or intra-nasally and is harmless in man. The Berlin-based company, ProBioGen, a company devoted to Intelligent Biopharmaceutical Solutions, prepared reversely engineered virus (R903/78), now available for experimental treatment of COVID-19. It is acid-resistant virus and therefore can be applied and absorbed systemically as an oral solution or applied as nose drops with no need to be injected.
In contrast to the available vaccines used to protect individuals from a disease caused by SARS-CoV-2, R903/78 that can be applied for treatment of COVID-19 after SARS-CoV-2 infection was already applied successfully in the past for treatment against other viral infections, hepatitis B and hepatitis C. The mechanism of anti-viral effects of R903/78 is based on its capacity to induce activation of type 1 interferons, Mother Nature natural mechanism for protection against viral infections and this is why treatment with the same R903/78 could be applied safely not only for the treatment of COVID-19 as well as COVID-19 mutations, but also against any future viral epidemics and possibly also against other diseases caused by currently incurable hazardous viral infection such as HIV-1 causing AIDS, Ebola or hepatitis B, and possibly also certain cancers caused by viral infections such as liver cancer (hepatoma) caused by hepatitis B or C.
Being in the cutting age of therapeutic procedures that can be mediated by harmless viruses, Prof. Slavin has been appointed as the Medical Director of the HepC Therapeutics and ProBioGen joint venture. Currently pilot clinical trials are being considered for post-exposure treatment of patients at risk with documented SARS-CoV-2 infection.